The global plasma protein therapeutics market has been envisaged in a report by Transparency Market Research (TMR) to witness the dominance of a few leading players securing a handsome share in the recent years. Octapharma, Baxalta, Grifols, and CSL Behring had achieved a maximum amount of share in the recent past, amongst which CSL Behring showcased its dominance in the market. The company provides a broad scope of products pertaining to applications in coagulation, wound healing, immunology, and critical care. With that mentioned, Grifols had held a commanding share on the part of intravenous immunoglobulin (IVIG) and alpha-1 antitrypsin markets.
Read Report Overview:
Between 2017 and 2024, the global plasma protein therapeutics market has been foreseen by TMR to rise at a 6.3.0% CAGR to expand to a US$31.8 bn valuation by the completion of the final forecast year. On the basis of segmentation by application, the market could testify the lead secured by primary immunodeficiency disorder (PID). By region, North America has been prognosticated to take the driver’s seat of the market with an anticipated valuation of US$13.8 bn to be attained by 2024.
Increasing Usage of Immunoglobulins in Treatment of PID Spurs Sales
The sales of plasma protein therapeutics have been foretold to gain momentum from the swelling usage of immunoglobulins in the treatment of primary immunodeficiency disorders (PID). The world plasma protein therapeutics market could create ample of prospects in the coming years on the back of the increasing application of human albumins in the treatment of burns, shocks, and blood loss. Furthermore, plasma protein therapeutics could be used as a drug formulation agent. There could be more opportunities rising with improved access to medicines in emerging economies and the emergence of innovative plasma-derived therapies.
Request Sample of the Report:
Other factors that could enhance growth in the world plasma protein therapeutics market are the advent of novel solutions for efficient and safe plasma collection and rising development of new indications. Increasing production of plasma-based drugs has raised the demand for immunoglobulins in the recent time. This too could amplify the rise of the global market.
Implementation of Stringent Regulatory Policies Fetters Growth
The international plasma protein therapeutics market has been envisioned to face a downside in its growth as a result of issues related to medical reimbursements and the implementation of tight regulatory policies. Additionally, there could be a possibility of bottlenecks being created due to the current complexity in biologics manufacturing. Nonetheless, there could be opportunities birthing on the back of increasing healthcare expenditure in developing countries of the world.
Request for Brochure:
This post was originally published on The Market Plan